home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
support.isiresearchsoft.com
/
support.isiresearchsoft.com.zip
/
support.isiresearchsoft.com
/
RefMan
/
capture
/
stncin.txt
< prev
next >
Wrap
Text File
|
1999-09-02
|
2KB
|
51 lines
<TITLE>STN-CIN</A> [<I>STN-CIN</I>] </TITLE><PRE>
L19 ANSWER 6 OF 17 COPYRIGHT 1994 ACS
AN 20(23):23660S CIN
SO J. Commer., 23 May 1991 (910523), p. 7A. ISSN: 0361-55-61 ; CODEN:
JCOCBM.
LA English
AB Solvay & Cie SA, of Belgium, and Upjohn Co. have formed an alliance
to market two central nervous system agents. Under the agreement,
Upjohn receives the rights from Solvay to market fluvoxamine, which
is currently marketed in all European markets and Canada for
treatment of depression. Also under the agreement, Solvay obtains
rights from Upjohn to market Xanax, used for the treatment of
clinical anxiety and anxiety associated with depression, in Europe,
the United States, Canada and the Philippines.
CC C (Sales)
ST *drug sales US
fluvoxamine drug sales US
depression drug sales US
Xanax drug sales Europe
Canada drug sales
Philippines drug sales
CO Upjohn Co.
Solvay & Cie. SA
GT *US; Europe; Canada; Philippines; Belgium
RN 28981-97-7 (XANAX)
***54739-18-3*** (FLUVOXAMINE)
L19 ANSWER 9 OF 17 COPYRIGHT 1994 ACS
AN 16(14):13189Y CIN
SO Manuf. Chem., Mar 1987 (870300), 58(3), p. 16. ISSN: 0262-4230;
CODEN: MCHMDI.
LA English
AB The first new antidepressant to be seen in the UK since 1982 has
been made available for hospital use by Duphar Laboratories. The
launch to GPs is expected next month. Faverin (fluvoxamine) is a
selective serotonin (5HT) reuptake blocker indicated for the
treatment of affective disorders characterised by persistent low
mood, impaired psychomotor activity and psychosomatic complaints.
CC C (Sales)
ST *drug sales UK
depression drug sales UK
Faverin fluvoxamine drug sales UK
CO Duphar Laboratories Ltd.
GT *UK
RN 116-29-0 (DUPHAR)
***54739-18-3*** (FLUVOXAMINE)
50-67-9Q, 65277-64-7Q (SEROTONIN)
</PRE>